Conditional cell-wall mutants of Saccharomyces cerevisiae as delivery vehicles for therapeutic agents in vivo to the GI tract

Walid A M Omara, Bharat M. Rash, Andrew Hayes, Martin S J Wickham, Stephen G. Oliver, Lubomira I. Stateva

    Research output: Contribution to journalArticlepeer-review

    Abstract

    Strains of Saccharomyces cerevisiae capable of lysis upon conditional down-regulation of cell-wall biogenesis genes (SRB1 and PKC1) have been reported. Here, we show that they lyse and release recombinant protein not only under laboratory conditions, but (more importantly) under conditions found in the human stomach and duodenum. These findings provide proof that, in principle, such conditional lysis strains could be used as an integral part of a system for the oral delivery of therapeutic proteins. However, the current mechanism of conditional lysis is based on the use of the MET3 promoter which requires addition of methionine and cysteine for down-regulation of SRB1 and PKC1. This requirement makes it difficult to apply in vivo. We reasoned that promoters, suitable for in vivo down-regulation of lysis-inducing genes, could be identified amongst yeast genes whose transcript abundance is reduced under conditions found in the human gut. A microarray experiment identified a number of candidate genes with significantly reduced transcript levels under simulated human gut conditions. The greatest effects were seen with ANB1, TIR1, and MF(ALPHA). 2), and we propose that their promoters have the potential to be used in vivo to achieve yeast lysis in the gut. © 2010 Elsevier B.V.
    Original languageEnglish
    Pages (from-to)136-143
    Number of pages7
    JournalJournal of biotechnology
    Volume147
    Issue number2
    DOIs
    Publication statusPublished - May 2010

    Keywords

    • Human gut
    • Lysis mutants
    • Oral delivery
    • Regulatable promoters
    • Therapeutics
    • Yeast

    Fingerprint

    Dive into the research topics of 'Conditional cell-wall mutants of Saccharomyces cerevisiae as delivery vehicles for therapeutic agents in vivo to the GI tract'. Together they form a unique fingerprint.

    Cite this